Clinical Trial Update: Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial assessing whether TMPRSS2-ETS gene status predicts response to enzalutamide in hormone-refractory prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Hormone-refractory Prostate Cancer | Phase 2 | Status: COMPLETED